Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name H19
   Synonyms H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2
   Region GRCh38_11:1995176-2001470    Sequence
   Ensembl ENSG00000130600
   RefSeq NR_002196
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name bladder cancer
   ICD-0-3 C67  
   Methods qPCR, RNAi, RIP, Luciferase reporter assay, in vitro knockdown etc.
   Sample bladder cancer tissues, cell lines (RT4, RT112, DSH1, 253J, TCCSUP etc.)
   Expression Pattern up-regulated
   Function Description

Here we found that H19 levels are remarkably increased in bladder cancer tissues, and upregulated H19 promotes bladder cancer cell migration in vitro and in vivo. H19 is associated with enhancer of EZH2, and that this association results in Wnt/B-Catenin activation and subsequent downregulation of E-cadherin. A significant negative correlation is also observed between H19 levels and E-cad levels in vivo. upregulated H19 enhances bladder cancer metastasis by associating with EZH2 and inhibiting E-cad expression.

   Pubmed ID 23354591
   Year 2013
   Title Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression.
   External Links
   Links for  H19 GenBank       HGNC       lncrnadb       Noncode
   Links for  bladder cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.